SynthesisScientific reports2016
Plasma prolactin and breast cancer risk: a meta- analysis.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Antipsychotic therapy and breast cancer risk: a comprehensive systematic review and meta-analysis.Breast cancer (Tokyo, Japan) · 2026Pooled it
- Risk factors for breast cancer: an umbrella review of observational cohort studies and causal relationship analysis.Frontiers in oncology · 2025Pooled it
- Causal relationship between cannabis use and cancer: a genetically informed perspective.Journal of cancer research and clinical oncology · 2023Pooled it
- Association of Schizophrenia With the Risk of Breast Cancer Incidence: A Meta-analysis.JAMA psychiatry · 2018Pooled it
- Effects of Estradiol/Micronized Progesterone vs. Conjugated Equine Estrogens/Medroxyprogesterone Acetate on Breast Cancer Gene Expression in Healthy Postmenopausal Women.International journal of molecular sciences · 2023Trial
- Nutrition Across the Life Course and Risk of Young-Onset Breast Cancer: Mechanisms, Evidence, and Prevention Opportunities.Nutrients · 2026Review
- Article
- Antipsychotic-induced hyperprolactinemia: Toxicologic mechanism and the increased breast cancer risk.Toxicology reports · 2025Review
- Breast cancer risk among women with schizophrenia and association with duration of antipsychotic use: population-based cohort study in South Korea.The British journal of psychiatry : the journal of mental science · 2025Article
- Aripiprazole use and lowering the risk of breast cancer in patient with schizophrenia in a national cohort study.PloS one · 2025Article
- Conception and Concern: A Review of Breast Cancer Risk in Assisted Reproductive Technology.International journal of biological sciences · 2025Review
- The influence of two neurohormones on breast cancer: prolactin and melatonin.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Severity and influencing factors of hyperprolactinemia in hospitalized schizophrenia patients: a cross-sectional study.Frontiers in psychiatry · 2025Article
- Current trends in breast cancer genetics, risk factors, and screening strategies.Journal of biological methods · 2025Review
- Plasma prolactin and postmenopausal breast cancer risk: a pooled analysis of four prospective cohort studies.Breast cancer research : BCR · 2024Article
- Effects of antipsychotic drugs during radiotherapy in breast cancer in South Korea: a retrospective cohort study.Scientific reports · 2024Article
- Investigating the Relationship between Schizophrenia and Incidence Risk of Breast Cancer: A Systematic Review and Meta-Analysis of Cohort Studies.Iranian journal of psychiatry · 2024Review
- Novel FFPE proteomics method suggests prolactin induced protein as hormone induced cytoskeleton remodeling spatial biomarker.Communications biology · 2024Article
- Serum Prolactin Levels as a Novel, Practical Marker for Predicting Malignant Diseases of the Breast.Cureus · 2024Article
- Sex-specific outcomes in cancer therapy: the central role of hormones.Frontiers in medical technology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common cancer among women, and its incidence is on a constant rise. Previous studies suggest that higher levels of plasma prolactin are associated with escalated risk of breast cancer, however, these results are contradictory and inconclusive. PubMed and Medline were used to search and identify published observational studies that assessed the relationship between plasma prolactin levels and the risk of breast cancer. The pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using a fixed-effects or random-effects model. A total of 7 studies were included in our analysis. For the highest versus lowest levels of plasma prolactin, the pooled RR (95% CI) of breast cancer were 1.16 (1.04, 1.29). In subgroup analyses, we found a positive association between plasma prolactin levels and the risk of breast cancer among the patients who were postmenopausal, ER(+)/PR(+) or in situ and invasive carcinoma. However, this positive association was not detected in the premenopausal and ER(-)/PR(-) patients. In conclusion, the present study provides evidence supporting a significantly positive association between plasma prolactin levels and the risk of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.